vs
Side-by-side financial comparison of JEWETT CAMERON TRADING CO LTD (JCTC) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $8.7M, roughly 1.1× JEWETT CAMERON TRADING CO LTD). JEWETT CAMERON TRADING CO LTD runs the higher net margin — -45.6% vs -60.3%, a 14.8% gap on every dollar of revenue. On growth, JEWETT CAMERON TRADING CO LTD posted the faster year-over-year revenue change (-6.6% vs -49.9%). Over the past eight quarters, JEWETT CAMERON TRADING CO LTD's revenue compounded faster (2.5% CAGR vs -6.7%).
Jewett Cameron Trading Co Ltd (ticker JCTC) is a US-based distribution firm offering construction hardware, industrial supplies, outdoor living, and home improvement goods. It serves retail, commercial construction, and wholesale clients across North America, with core segments in building materials and outdoor recreation.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
JCTC vs PLX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.7M | $9.1M |
| Net Profit | $-3.9M | $-5.5M |
| Gross Margin | -12.5% | 49.4% |
| Operating Margin | -43.7% | -51.1% |
| Net Margin | -45.6% | -60.3% |
| Revenue YoY | -6.6% | -49.9% |
| Net Profit YoY | -498.8% | -184.8% |
| EPS (diluted) | $-1.12 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $8.7M | $9.1M | ||
| Q3 25 | $10.4M | $17.9M | ||
| Q2 25 | $12.6M | $15.7M | ||
| Q1 25 | $9.1M | $10.1M | ||
| Q4 24 | $9.3M | $18.2M | ||
| Q3 24 | $13.2M | $18.0M | ||
| Q2 24 | $15.9M | $13.5M | ||
| Q1 24 | $8.2M | — |
| Q4 25 | $-3.9M | $-5.5M | ||
| Q3 25 | $-2.2M | $2.4M | ||
| Q2 25 | $-649.6K | $164.0K | ||
| Q1 25 | $-573.1K | $-3.6M | ||
| Q4 24 | $-658.7K | $6.5M | ||
| Q3 24 | $-190.5K | $3.2M | ||
| Q2 24 | $154.9K | $-2.2M | ||
| Q1 24 | $-534.1K | — |
| Q4 25 | -12.5% | 49.4% | ||
| Q3 25 | 8.2% | 53.4% | ||
| Q2 25 | 15.0% | 62.5% | ||
| Q1 25 | 20.1% | 19.1% | ||
| Q4 24 | 18.3% | 78.7% | ||
| Q3 24 | 14.5% | 53.4% | ||
| Q2 24 | 18.6% | 29.8% | ||
| Q1 24 | 25.1% | — |
| Q4 25 | -43.7% | -51.1% | ||
| Q3 25 | -13.8% | 11.9% | ||
| Q2 25 | -5.5% | 7.5% | ||
| Q1 25 | -8.5% | -41.0% | ||
| Q4 24 | -9.3% | 39.6% | ||
| Q3 24 | -2.3% | 22.2% | ||
| Q2 24 | 0.3% | -18.0% | ||
| Q1 24 | -8.8% | — |
| Q4 25 | -45.6% | -60.3% | ||
| Q3 25 | -21.7% | 13.2% | ||
| Q2 25 | -5.2% | 1.0% | ||
| Q1 25 | -6.3% | -35.8% | ||
| Q4 24 | -7.1% | 35.6% | ||
| Q3 24 | -1.4% | 18.0% | ||
| Q2 24 | 1.0% | -16.4% | ||
| Q1 24 | -6.5% | — |
| Q4 25 | $-1.12 | $-0.06 | ||
| Q3 25 | $-0.65 | $0.03 | ||
| Q2 25 | $-0.18 | $0.00 | ||
| Q1 25 | $-0.16 | $-0.05 | ||
| Q4 24 | $-0.19 | $0.10 | ||
| Q3 24 | $-0.05 | $0.03 | ||
| Q2 24 | $0.04 | $-0.03 | ||
| Q1 24 | $-0.15 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.0M | $14.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $16.8M | $48.2M |
| Total Assets | $23.2M | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.0M | $14.7M | ||
| Q3 25 | $226.2K | $13.6M | ||
| Q2 25 | $1.2M | $17.9M | ||
| Q1 25 | $435.6K | $19.5M | ||
| Q4 24 | $3.0M | $19.8M | ||
| Q3 24 | $4.9M | $27.4M | ||
| Q2 24 | $1.1M | $23.4M | ||
| Q1 24 | $1.1M | — |
| Q4 25 | $16.8M | $48.2M | ||
| Q3 25 | $20.8M | $52.9M | ||
| Q2 25 | $23.0M | $49.9M | ||
| Q1 25 | $23.7M | $45.2M | ||
| Q4 24 | $24.2M | $43.2M | ||
| Q3 24 | $24.9M | $32.4M | ||
| Q2 24 | $25.0M | $28.6M | ||
| Q1 24 | $24.9M | — |
| Q4 25 | $23.2M | $82.3M | ||
| Q3 25 | $25.5M | $82.3M | ||
| Q2 25 | $29.2M | $78.5M | ||
| Q1 25 | $27.6M | $73.9M | ||
| Q4 24 | $26.7M | $73.4M | ||
| Q3 24 | $27.5M | $61.6M | ||
| Q2 24 | $28.3M | $91.5M | ||
| Q1 24 | $29.0M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.3M | $2.0M |
| Free Cash FlowOCF − Capex | — | $1.6M |
| FCF MarginFCF / Revenue | — | 17.8% |
| Capex IntensityCapex / Revenue | 0.0% | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.3M | $2.0M | ||
| Q3 25 | $-636.4K | $-3.7M | ||
| Q2 25 | $-1.6M | $-5.2M | ||
| Q1 25 | $-2.6M | $-5.1M | ||
| Q4 24 | $-1.8M | $4.0M | ||
| Q3 24 | $3.8M | $4.1M | ||
| Q2 24 | $14.5K | $-3.6M | ||
| Q1 24 | $-2.4M | — |
| Q4 25 | — | $1.6M | ||
| Q3 25 | $-658.0K | $-4.2M | ||
| Q2 25 | $-1.7M | $-5.7M | ||
| Q1 25 | $-2.6M | $-5.4M | ||
| Q4 24 | $-1.8M | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | $-96.1K | $-3.8M | ||
| Q1 24 | — | — |
| Q4 25 | — | 17.8% | ||
| Q3 25 | -6.3% | -23.7% | ||
| Q2 25 | -13.1% | -36.2% | ||
| Q1 25 | -28.8% | -53.0% | ||
| Q4 24 | -19.6% | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | -0.6% | -28.1% | ||
| Q1 24 | — | — |
| Q4 25 | 0.0% | 4.4% | ||
| Q3 25 | 0.2% | 2.8% | ||
| Q2 25 | 0.3% | 2.8% | ||
| Q1 25 | 0.2% | 3.0% | ||
| Q4 24 | 0.4% | 2.3% | ||
| Q3 24 | 0.0% | 0.5% | ||
| Q2 24 | 0.7% | 1.3% | ||
| Q1 24 | 0.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | 0.09× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JCTC
| Lawn Garden Pet And Other | $7.4M | 86% |
| Industrial Wood Products | $1.2M | 14% |
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
